{"title":"Assessing the burden and trends of pancreatitis in India from 1990-2021: An analysis of the global burden of disease database.","authors":"H Shafeeq Ahmed","doi":"10.1007/s12664-025-01869-2","DOIUrl":"https://doi.org/10.1007/s12664-025-01869-2","url":null,"abstract":"<p><strong>Background and aim: </strong>Pancreatitis poses a growing health concern globally, yet its burden in India has not been comprehensively assessed over time. This study aimed to quantify the national and sub-national trends in incidence, prevalence, mortality and disability burden of pancreatitis in India from 1990 to 2021, using Global Burden of Disease (GBD) 2021 data.</p><p><strong>Methods: </strong>Data on six core indicators: incidence, prevalence, deaths, disability-adjusted life years (DALYs), years of life lost (YLLs) and years lived with disability (YLDs) were extracted from the GBD database. Age-standardized rates (ASRs) per 100,000 population were analyzed across 31 Indian states and union territories. Trends were evaluated by age, sex and region.</p><p><strong>Results: </strong>From 1990 to 2021, incident cases rose from 229,614 (95% UI: 190,053-274,618) to 523,074 (95% UI: 435,284-625,178) and prevalence rose from 249,067 (95% UI: 169,900-342,317) to 547,618 (95% UI: 369,410-750,696). The age-standardized incidence rate increased modestly from 32.78 (95% UI: 27.25-38.72) to 36.76 (95% UI: 30.52-43.44), while the prevalence rate rose from 37.83 (95% UI: 25.53-51.76) to 39.70 (95% UI: 26.84-54.45). The ASR for deaths declined from 2.24 (95% UI: 1.57-3.12) to 1.71 (95% UI: 1.27-2.25) and the DALY rate from 77.69 (95% UI: 57.42-111.80) to 56.82 (95% UI: 43.50-73.46). Male ASRs remained consistently higher than female. Higher Socio-Demographic Index (SDI) states showed increased YLDs and reduced premature mortality.</p><p><strong>Conclusion: </strong>The pancreatitis burden in India has increased substantially, with notable regional and sex-based differences. These findings point out the need for early diagnosis, targeted interventions in high-burden states and improved outpatient care to manage chronic morbidity.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Child-Turcotte-Pugh score-based modified anti-tubercular treatment in patients with decompensated cirrhosis with tuberculosis: A two-year retrospective observational study from North India.","authors":"Juned Ahmad","doi":"10.1007/s12664-025-01860-x","DOIUrl":"https://doi.org/10.1007/s12664-025-01860-x","url":null,"abstract":"<p><strong>Background: </strong>Management of tuberculosis in decompensated cirrhosis is challenging, as the risk of severe liver failure is markedly increased if hepatotoxicity develops secondary to anti-tubercular treatment (ATT). Child-Turcotte-Pugh (CTP) score-based ATT by Dhiman et al. proposed that the number of hepatotoxic drugs should be two, one and none in CTP scores of ≤ 7, 8-10 and ≥ 11, respectively. We present here our retrospective observational study of treating tuberculosis in patients with decompensated cirrhosis utilizing the above-mentioned CTP-based ATT regimens.</p><p><strong>Methods: </strong>A retrospective observational study utilizing electronic data search was conducted on the application-based software for the duration from April 2022 to April 2024. On the software, decompensated cirrhosis with tuberculosis patients were already tagged. The modified ATT regimens (weight-based) were as per the CTP score. With CTP score ≥ 11, no hepatotoxic drug was included: Intensive Phase -ELA (Ethambutol, Levofloxacin and Amikacin); Continuation Phase: EL. With CTP scores 8-10, 1 hepatotoxic drug (rifampicin preferred) was included; Intensive Phase: RELA, R Rifampicin; Continuation Phase: REL. CTP score ≤ 7 received two hepatotoxic drugs, Intensive Phase: HREL, H Isoniazid, Continuation Phase: HRE. The duration of ATT's continuation phase was 12-18 months.</p><p><strong>Results: </strong>Of 155 patients with decompensated cirrhosis, 21 (13.5%) had concomitant tuberculosis. CTP score-based modified ATT was administered to all 21 during the Intensive phase. Drug-induced hepatotoxicity developed in four patients (19.1%) during the intensive phase. After the intensive phase, two patients were lost to follow-up. Out of 19 patients who completed the continuation phase, 15 (78.9%) had a resolution of tuberculosis and four (21.1%) died. The cause for death in all four patients was related to cirrhosis.</p><p><strong>Conclusion: </strong>As per our study, patients with decompensated cirrhosis tolerated the CTP-score-based modified ATT and almost 80% had a resolution of tuberculosis.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Revisiting thiopurines and therapeutic drug monitoring in IBD: Insights and implications in the Indian context.","authors":"Arshdeep Singh, Ajit Sood","doi":"10.1007/s12664-025-01864-7","DOIUrl":"https://doi.org/10.1007/s12664-025-01864-7","url":null,"abstract":"","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anand V Kulkarni, Hardik Rughwani, D Nageshwar Reddy
{"title":"Assessing portal hypertension and its impact on carbon emissions.","authors":"Anand V Kulkarni, Hardik Rughwani, D Nageshwar Reddy","doi":"10.1007/s12664-025-01847-8","DOIUrl":"https://doi.org/10.1007/s12664-025-01847-8","url":null,"abstract":"","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prevalence of hepatitis B infection and its associated factors in rural South India: A valuable investigation.","authors":"Jing Zhang, Lin-Jing Wang, Jin-Feng Chi","doi":"10.1007/s12664-025-01862-9","DOIUrl":"https://doi.org/10.1007/s12664-025-01862-9","url":null,"abstract":"","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Confronting the hidden cost of diagnostic delay in diagnosis and treatment initiation: Inflammatory bowel disease as model to understand chronic diseases.","authors":"Deepshikha Sharma, Nidhi Gupta, Shankar Prinja","doi":"10.1007/s12664-025-01858-5","DOIUrl":"https://doi.org/10.1007/s12664-025-01858-5","url":null,"abstract":"","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reply to: \"Overlap of 'disorders of gut-brain interaction': A type of diseases that require special attention\" and \"Comment on \"Overlap of 'disorders of gut-brain interaction' and their impact on quality of life and somatization in a tertiary care center\".","authors":"Manjeet Kumar Goyal, Prerna Goyal, Omesh Goyal, Ajit Sood","doi":"10.1007/s12664-025-01857-6","DOIUrl":"https://doi.org/10.1007/s12664-025-01857-6","url":null,"abstract":"","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"HLA association with azathioprine-induced pancreatitis in patients with inflammatory bowel disease: A case series.","authors":"Sidharth Harindranath, Rajeshwari B, Suchita J, Anand Deshpande, Devendra Desai","doi":"10.1007/s12664-025-01813-4","DOIUrl":"https://doi.org/10.1007/s12664-025-01813-4","url":null,"abstract":"<p><strong>Background: </strong>Azathioprine (AZA)-induced pancreatitis is a significant adverse event affecting patients with inflammatory bowel disease (IBD). A genetic association with HLA-DRB1*07 and HLA-DQA1*02 alleles polymorphisms has been reported, but its prevalence and impact on Asian patients with IBD remain unclear.</p><p><strong>Methods: </strong>A retrospective review of a prospectively maintained database of patients with IBD was done from January 2005 till December 2024. Patients who developed pancreatitis were tested for HLA association with HLA class II-DRB1*07 and HLA-DQA1*02 alleles. Duration of AZA, dose of AZA and other risk factors such as smoking, alcohol intake, steroid administration, previous history of pancreatitis and any other risk factors for pancreatitis were noted. These patients were compared with a matched control group of non-IBD patients undergoing human leukocyte antigen (HLA) typing for other indications.</p><p><strong>Results: </strong>Of 1751 patients with IBD, 441 (25.1%) were exposed to AZA 12/441 (2.7%) developed azathioprine-induced pancreatitis. Patients with pancreatitis had a significantly higher prevalence of the HLA-DRB1*07 and HLA-DQA1*02 haplotype compared to controls (8/12; 66.6% vs. 1877/7361; 25.4% p = 0.001089). The onset of pancreatitis occurred within a median of 15 days of initiation of AZA, with all cases being mild in severity. Rechallenge confirmed causality in one patient.</p><p><strong>Conclusion: </strong>Azathioprine-induced pancreatitis occurred in 2.7% patients. The class-II HLA-DRB1*07 and HLA-DQA1*02 is an important marker for AZA-induced pancreatitis risk. Rechallenge should be avoided in patients with this HLA antigen. More data is required for pre-emptive HLA testing prior to initiation of azathioprine.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Glucagon-like peptide 1 analogues in patients with inflammatory bowel disease with metabolic disorders: More than weight loss?","authors":"Chhagan Lal Birda, Shaji Sebastian","doi":"10.1007/s12664-025-01854-9","DOIUrl":"https://doi.org/10.1007/s12664-025-01854-9","url":null,"abstract":"","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}